Rimi

Rimi Bio is an innovative biotechnology company focused on the discovery and development of next-generation biologics for the treatment of cancer and autoimmune disorders. The company utilizes proprietary antibody engineering platforms to create conditionally activated therapies and multi-specific antibodies designed to improve the therapeutic index and overcome resistance in difficult-to-treat diseases. By ensuring that therapeutic activity is primarily localized within the tumor microenvironment, Rimi Bio aims to reduce systemic toxicity and enhance efficacy. Headquartered in Shanghai with research and development operations in South San Francisco, the company is advancing a diverse pipeline of candidates, including programs targeting Claudin 18.2.